108 related articles for article (PubMed ID: 38849885)
1. The FABD domain is critical for the oncogenicity of BCR/ABL in chronic myeloid leukaemia.
Zheng R; Wei W; Liu S; Zeng D; Yang Z; Tang J; Tan J; Huang Z; Gao M
Cell Commun Signal; 2024 Jun; 22(1):314. PubMed ID: 38849885
[TBL] [Abstract][Full Text] [Related]
2. Effect of HSP90AB1 and CC domain interaction on Bcr-Abl protein cytoplasm localization and function in chronic myeloid leukemia cells.
Peng Y; Huang Z; Zhou F; Wang T; Mou K; Feng W
Cell Commun Signal; 2021 Jul; 19(1):71. PubMed ID: 34217296
[TBL] [Abstract][Full Text] [Related]
3. Interplay between kinase domain autophosphorylation and F-actin binding domain in regulating imatinib sensitivity and nuclear import of BCR-ABL.
Preyer M; Vigneri P; Wang JY
PLoS One; 2011 Feb; 6(2):e17020. PubMed ID: 21347248
[TBL] [Abstract][Full Text] [Related]
4. Induction of apoptosis in imatinib sensitive and resistant chronic myeloid leukemia cells by efficient disruption of bcr-abl oncogene with zinc finger nucleases.
Huang N; Huang Z; Gao M; Luo Z; Zhou F; Liu L; Xiao Q; Wang X; Feng W
J Exp Clin Cancer Res; 2018 Mar; 37(1):62. PubMed ID: 29554925
[TBL] [Abstract][Full Text] [Related]
5. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
Aljedai A; Buckle AM; Hiwarkar P; Syed F
PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
[TBL] [Abstract][Full Text] [Related]
6. Targeted disruption of the
Zeng J; Liang X; Duan L; Tan F; Chen L; Qu J; Li J; Li K; Luo D; Hu Z
Acta Biochim Biophys Sin (Shanghai); 2024 Apr; 56(4):525-537. PubMed ID: 38414349
[TBL] [Abstract][Full Text] [Related]
7. Growth of chronic myeloid leukemia cells is inhibited by infection with Ad-SH2-HA adenovirus that disrupts Grb2-Bcr-Abl complexes.
Peng Z; Luo HW; Yuan Y; Shi J; Huang SF; Li CL; Cao WX; Huang ZG; Feng WL
Oncol Rep; 2011 May; 25(5):1381-8. PubMed ID: 21369701
[TBL] [Abstract][Full Text] [Related]
8. Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.
Wu LX; Wu Y; Chen RJ; Liu Y; Huang LS; Lou LG; Zheng ZH; Chen YZ; Xu JH
Acta Pharmacol Sin; 2014 Mar; 35(3):401-9. PubMed ID: 24487968
[TBL] [Abstract][Full Text] [Related]
9. Blockade of Y177 and Nuclear Translocation of Bcr-Abl Inhibits Proliferation and Promotes Apoptosis in Chronic Myeloid Leukemia Cells.
Li Q; Huang Z; Gao M; Cao W; Xiao Q; Luo H; Feng W
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28257089
[TBL] [Abstract][Full Text] [Related]
10. β-Arrestin1 promotes the progression of chronic myeloid leukaemia by regulating BCR/ABL H4 acetylation.
Qin R; Li K; Qi X; Zhou X; Wang L; Zhang P; Zou L
Br J Cancer; 2014 Jul; 111(3):568-76. PubMed ID: 24937675
[TBL] [Abstract][Full Text] [Related]
11. Localization of BCR-ABL to F-actin regulates cell adhesion but does not attenuate CML development.
Wertheim JA; Perera SA; Hammer DA; Ren R; Boettiger D; Pear WS
Blood; 2003 Sep; 102(6):2220-8. PubMed ID: 12791659
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
Lin TY; Chen KC; Liu HJ; Liu AJ; Wang KL; Shih CM
PLoS One; 2016; 11(5):e0156260. PubMed ID: 27228340
[TBL] [Abstract][Full Text] [Related]
13. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.
Hamilton A; Helgason GV; Schemionek M; Zhang B; Myssina S; Allan EK; Nicolini FE; Müller-Tidow C; Bhatia R; Brunton VG; Koschmieder S; Holyoake TL
Blood; 2012 Feb; 119(6):1501-10. PubMed ID: 22184410
[TBL] [Abstract][Full Text] [Related]
14. A novel fusion circular RNA F-circBA1 derived from the
Tan Y; Huang Z; Wang X; Dai H; Jiang G; Feng W
Bioengineered; 2021 Dec; 12(1):4816-4827. PubMed ID: 34346842
[TBL] [Abstract][Full Text] [Related]
15. Induction of apoptosis by directing oncogenic Bcr-Abl into the nucleus.
Huang ZL; Gao M; Li QY; Tao K; Xiao Q; Cao WX; Feng WL
Oncotarget; 2013 Dec; 4(12):2249-60. PubMed ID: 24158537
[TBL] [Abstract][Full Text] [Related]
16. Role of the C-terminal actin binding domain in BCR/ABL-mediated survival and drug resistance.
Underhill-Day N; Pierce A; Thompson SE; Xenaki D; Whetton AD; Owen-Lynch PJ
Br J Haematol; 2006 Mar; 132(6):774-83. PubMed ID: 16487179
[TBL] [Abstract][Full Text] [Related]
17. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
[TBL] [Abstract][Full Text] [Related]
18. Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
Mukherjee K; Sha X; Magimaidas A; Maifrede S; Skorski T; Bhatia R; Hoffman B; Liebermann DA
Oncotarget; 2017 Feb; 8(7):10809-10821. PubMed ID: 28086219
[TBL] [Abstract][Full Text] [Related]
19. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway.
Huang R; Liu H; Chen Y; He Y; Kang Q; Tu S; He Y; Zhou X; Wang L; Yang J; Wu A; Li Y
Oncol Rep; 2018 Jan; 39(1):119-128. PubMed ID: 29192326
[TBL] [Abstract][Full Text] [Related]
20. TAT-CC fusion protein depresses the oncogenicity of BCR-ABL in vitro and in vivo through interrupting its oligomerization.
Huang ZL; Gao M; Ji MS; Tao K; Xiao Q; Zhong L; Zeng JM; Feng WL
Amino Acids; 2013 Feb; 44(2):461-72. PubMed ID: 22782217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
